Professor, Medicine, UCLA School of Medicine
Oncology
Dr. Fairooz F. Kabbinavar, MD
|
|
Give Review
Dr. Fairooz F. Kabbinavar is an expert in the field of Oncology. He attended Indira Gandhi Medical College. He received 1 awards: "Super Doctor". Fairooz Kabbinavar has written publications. He has 80 publications published with PubMed. The lastest paper is: 'Intra-arterial Cereport (RMP-7) and carboplatin: a dose escalation study for recurrent malignant gliomas.' He is registered with Medicare.
Publications
- Individual Patient Data Analysis of Progression-Free Survival Versus Overall Survival As a First-Line End Point for Metastatic Colorectal Cancer in Modern Randomized T...
- The High-Dose Aldesleukin "Select" Trial: A Trial to Prospectively Validate Predictive Models of Response Treatment in Patients with Metastatic Renal Cell Carcinoma.
- Biomarker Analyses from a Randomized, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab with or without Erlotinib as Maintenance Therapy for the Treatment of ...
- Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung Cancer.
- ATLAS: Randomized, Double-Blind, Placebo-Controlled, Phase IIIB Trial Comparing Bevacizumab Therapy With or Without Erlotinib, After Completion of Chemotherapy, With B...
- Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma.
- PD-0332991, a Potent and Selective Inhibitor of Cyclin-dependent Kinase 4/6, Demonstrates Inhibition of Proliferation in Renal Cell Carcinoma at Nanomolar Concentratio...
- Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer: Pooled Analysis From Seven Randomized Controlled Trials.
- Dacomitinib, an Irreversible Pan-ErbB Inhibitor Significantly Abrogates Growth in Head and Neck Cancer Models That Exhibit Low Response to Cetuximab.
- Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma.
- Gain of chromosome 8q is associated with metastases and poor survival of patients with clear cell renal cell carcinoma.
- Systemic therapy for metastatic renal cell carcinoma: a review and update.
- Pathological, immunohistochemical and cytogenetic features of papillary renal cell carcinoma with clear cell features.
- Development and external validation of a nomogram predicting disease specific survival after nephrectomy for papillary renal cell carcinoma.
- Fuhrman grade provides higher prognostic accuracy than nucleolar grade for papillary renal cell carcinoma.
- Histologic evaluation of metastases in renal cell carcinoma with sarcomatoid transformation and its implications for Systemic therapy.
- CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis.
- Presence of tumor necrosis is not a significant predictor of survival in clear cell renal cell carcinoma: higher prognostic accuracy of extent based rather than presen...
- Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy.
- Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma.
- Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma.
- Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal Cancer: pooled analysis of cohorts of older patients from two randomized cl...
- Pathobiology and prognosis of chromophobe renal cell carcinoma.
- Cancer-specific survival outcomes among patients treated during the cytokine era of kidney Cancer (1989-2005): a benchmark for emerging targeted Cancer therapies.
- Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival.
- Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colo...
- Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas.
- The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma.
- Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma.
- Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell Cancer.
- Prognostic factors for renal cell carcinoma with tumor thrombus extension.
- Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experience.
- Metachronous bilateral renal cell carcinoma: risk assessment, prognosis and relevance of the primary-free interval.
- Phase II study of pemetrexed for second-line treatment of transitional cell Cancer of the urothelium.
- Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal Cancer: results of a randomized phase II trial.
- Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal Cancer.
- Can inhibition of angiogenic pathways increase the efficacy of intravenous 5-fluorouracil-based regimens?
- Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian Cancer cells.
- Salvage-targeted kidney Cancer therapy in patients progressing on high-dose interleukin-2 immunotherapy: the UCLA experience.
- Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal Cancer treated with 5-fluorouracil-based regimens irrespective of...
- Functional and oncological outcomes of partial nephrectomy of solitary kidneys.
- Clinical outcomes in elderly patients with metastatic colorectal Cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study.
- A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast Cancer (TORI B01).
- Chromosome 9p deletions identify an aggressive phenotype of clear cell renal cell carcinoma.
- Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung Cancer (ZODIAC): a double-blind, randomised, phase 3...
- A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma.
- A Randomized, Phase II, Biomarker-Selected Study Comparing Erlotinib to Erlotinib Intercalated With Chemotherapy in First-Line Therapy for Advanced Non-Small-Cell Lung...
- Regarding ''Treatment of colorectal Cancer with and without bevacizumab: a phase III study''.
- Angiogenesis and angiogenic inhibitors in renal cell carcinoma.
- Performance status and cytoreDuctive nephrectomy: redefining management in patients with poor performance.
- Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic co...
- Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal Cancer.
- Surgical wound healing complications in metastatic colorectal Cancer patients treated with bevacizumab.
- Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab.
- Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal Cancer.
- Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
- A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period.
- Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal Cancer.
- Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metas...
- Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen-independent prostate carcinoma.
- Two studies evaluating irinotecan treatment for recurrent Malignant glioma using an every-3-week regimen.
- Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate Cancer.
- Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal Cancer.
- Irinotecan treatment for recurrent Malignant glioma using an every-3-week regimen.
- A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate Cancer.
- Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts.
- Biologic effects of heregulin/neu differentiation factor on normal and malignant human Breast and ovarian epithelial cells.
- Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast Cancers.
- Intra-arterial Cereport (RMP-7) and carboplatin: a dose escalation study for recurrent malignant Gliomas.
- Intra-arterial carboplatin chemotherapy for Brain tumors: a dose escalation study based on cerebral blood flow.
- Anti-VEGF antibody bevacizumab (Avastin) with 5FU/LV as third line treatment for colorectal Cancer.
- Clinicopathological features and prognosis of synchronous bilateral renal cell carcinoma: an international multicentre experience.
- A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate Cancer.
- Neoadjuvant targeted therapy and advanced kidney Cancer: observations and implications for a new treatment paradigm.
- Prognostic value of microvascular invasion in predicting the Cancer specific survival and risk of metastatic disease in renal cell carcinoma: a multicenter investigation.
- The chromophobe tumor grading System is the preferred grading scheme for chromophobe renal cell carcinoma.
- A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell...
- Effect of bevacizumab in older patients with metastatic colorectal Cancer: pooled analysis of four randomized studies.
- Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal Cancer: the BRiTE observational cohort study.
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anemia
- Bile Duct Cancer
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Super Doctor
Education
-
UCLA Medical Center -
Beth Israel Deaconess Medical Center -
Indira Gandhi Medical College
Hospital
-
Ronald Reagan UCLA Medical Center -
Santa Monica-UCLA Medical Center and Orthopaedic Hospital
Drug Facts
| NPI NUMBER | 1801871819 | |
| NPPES Provider LastName | KABBINAVAR | |
| NPPES Provider FirstName | FAIROOZ | |
| NPPES Provider ZIPCode | 900953000 | |
| NPPES Provider State | CA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 255.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1801871819 |
| Last Name Of The Provider | KABBINAVAR |
| First Name Of The Provider | FAIROOZ |
| View All |
Similar Doctors
|
|
Dr. Ronald T. Mitsuyasu, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. John L. Barstis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eric C. McGary, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James S. Hu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Leonid M. Kleynberg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robin F. Eisner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Agustin A. Garcia, MD
This Doctor is OpenDoctor Recommended.
|